Reminder for uniQure N.V. Class Action Lawsuit

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 3 days ago

0mins

QURE+0.94%

Should l Buy QURE?

Source: PRnewswire

Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action lawsuit and potentially receive compensation without any out-of-pocket costs.
Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could affect potential compensation outcomes.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QURE

Wall Street analysts forecast QURE stock price to rise

10 Analyst Rating

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 17.090

Low

33.00

Averages

49.88

High

70.00

Current: 17.090

Low

33.00

Averages

49.88

High

70.00

Barclays

Eliana Merle

Equal Weight

downgrade

$31 -> $25

2026-03-23

Reason

Barclays

Eliana Merle

Price Target

$31 -> $25

AI Analysis

2026-03-23

downgrade

Equal Weight

Reason

Barclays analyst Eliana Merle lowered the firm's price target on uniQure to $25 from $31 and keeps an Equal Weight rating on the shares. While Vinay Prasad's departure from the FDA could be a positive, regulatory uncertainty continues for uniQure, the analyst tells investors in a research note. Barclays thinks a Phase 3 trial in Huntington's disease will likely be required for uniQure.

Mizuho

Neutral -> Outperform

upgrade

$12 -> $35

2026-03-10

Reason

Mizuho

Price Target

$12 -> $35

2026-03-10

upgrade

Neutral -> Outperform

Reason

Mizuho upgraded uniQure to Outperform from Neutral with a price target of $35, up from $12.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QURE

Unlock Now

About QURE

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Capricor's Former Executive Considered for FDA Biologics Chief

2 days agostocktwits

FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.

uniQure Faces Class Action Lawsuit Notification

2 days agoGlobenewswire

Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.

uniQure Faces Class Action Lawsuit Reminder

3 days agoPRnewswire

Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trading from September 24 to October 31, 2025, which could negatively impact the company's reputation and stock price.
False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, resulting in investor losses when the truth emerged.
Investor Rights Protection: The Schall Law Firm encourages investors who purchased uniQure securities during the class period to contact them before April 13, 2026, to participate in the lawsuit and seek compensation for losses, demonstrating a commitment to protecting investor rights.
Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, highlighting the importance of proactive participation in legal proceedings for investors.